

Florence Abravanel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3234916/publications.pdf>

Version: 2024-02-01

167
papers

12,562
citations

29994

54
h-index

27345

106
g-index

176
all docs

176
docs citations

176
times ranked

8594
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients. <i>American Journal of Transplantation</i> , 2022, 22, 322-323.	2.6	120
2	Anti-SARS-CoV-2 spike protein and neutralizing antibodies at 1 and 3 months after three doses of SARS-CoV-2 vaccine in a large cohort of solid organ transplant patients. <i>American Journal of Transplantation</i> , 2022, 22, 1467-1474.	2.6	37
3	Influence of the Delta Variant and Vaccination on the SARS-CoV-2 Viral Load. <i>Viruses</i> , 2022, 14, 323.	1.5	13
4	Humoral and Cellular Immune Responses of Solid Organ Transplant Patients on Belatacept to Three Doses of mRNA-Based Anti-SARS-CoV-2 Vaccine. <i>Vaccines</i> , 2022, 10, 354.	2.1	8
5	Novel T cell interferon gamma release assay (IGRA) using spike recombinant protein for COVID19 vaccine response and Nucleocapsid for SARS-Cov2 response. <i>Clinical Immunology</i> , 2022, 237, 108979.	1.4	12
6	Predictive Factors for Humoral Response After 2-dose SARS-CoV-2 Vaccine in Solid Organ Transplant Patients. <i>Transplantation Direct</i> , 2022, 8, e1248.	0.8	25
7	Diagnostic Performance of an Automated System for Assaying Anti-Hepatitis E Virus Immunoglobulins M and G Compared with a Conventional Microplate Assay. <i>Viruses</i> , 2022, 14, 1065.	1.5	5
8	Screening for SARS-CoV-2 antibodies among healthcare workers in a university hospital in southern France. <i>Journal of Infection</i> , 2021, 82, e29-e32.	1.7	14
9	An Evaluation of Hepatitis E Virus Molecular Typing Methods. <i>Clinical Chemistry</i> , 2021, 68, 181-191.	1.5	5
10	Effector memory CD8 T cell response elicits Hepatitis E Virus genotype 3 pathogenesis in the elderly. <i>PLoS Pathogens</i> , 2021, 17, e1009367.	2.1	16
11	Analyses of Clinical and Biological Data for French and Belgian Immunocompetent Patients Infected With Hepatitis E Virus Genotypes 4 and 3. <i>Frontiers in Microbiology</i> , 2021, 12, 645020.	1.5	6
12	Hepatitis E, what is the real issue?. <i>Liver International</i> , 2021, 41, 68-72.	1.9	6
13	Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients. <i>New England Journal of Medicine</i> , 2021, 385, 661-662.	13.9	728
14	Safety and Immunogenicity of Anti-SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants. <i>Annals of Internal Medicine</i> , 2021, 174, 1336-1338.	2.0	122
15	Rat Hepatitis E Virus: Presence in Humans in South-Western France?. <i>Frontiers in Medicine</i> , 2021, 8, 726363.	1.2	8
16	Fatal encephalitis and Borna Disease Virus seropositivity in two kidney transplant patients living in the same nonendemic area. <i>Transplant Infectious Disease</i> , 2021, 23, .	0.7	5
17	Adaptive lymphocyte profile analysis discriminates mild and severe forms of COVID-19 after solid organ transplantation. <i>Kidney International</i> , 2021, 100, 915-927.	2.6	4
18	Testing individual and pooled saliva samples for sars-cov-2 nucleic acid: a prospective study. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 101, 115478.	0.8	8

#	ARTICLE	IF	CITATIONS
19	Mobilization of $\hat{I}\hat{I}$ T Cells and IL-10 Production at the Acute Phase of Hepatitis E Virus Infection in Cytomegalovirus Carriers. <i>Journal of Immunology</i> , 2021, 206, 1027-1038.	0.4	5
20	Hepatitis E Virus Quasispecies in Cerebrospinal Fluid with Neurological Manifestations. <i>Vaccines</i> , 2021, 9, 1205.	2.1	8
21	Assessment of 4 Doses of SARS-CoV-2 Messenger RNA-Based Vaccine in Recipients of a Solid Organ Transplant. <i>JAMA Network Open</i> , 2021, 4, e2136030.	2.8	103
22	Evaluation of Three Quantitative Anti-SARS-CoV-2 Antibody Immunoassays. <i>Microbiology Spectrum</i> , 2021, 9, e0137621.	1.2	22
23	Hepatitis E Virus Infection: Neurological Manifestations and Pathophysiology. <i>Pathogens</i> , 2021, 10, 1582.	1.2	13
24	Hepatitis E virus replication in human intestinal cells. <i>Gut</i> , 2020, 69, 901-910.	6.1	58
25	Performance of the Xpert HBV Viral Load assay versus the Aptima Quant assay for quantifying hepatitis B virus DNA. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 96, 114946.	0.8	23
26	Does HEV subtype play a role in the severity of acute hepatitis E?. <i>Liver International</i> , 2020, 40, 333-337.	1.9	20
27	Ribavirin for Hepatitis E Virus Infection After Organ Transplantation: A Large European Retrospective Multicenter Study. <i>Clinical Infectious Diseases</i> , 2020, 71, 1204-1211.	2.9	74
28	Performance evaluation of the Vela Dx Sentosa next-generation sequencing system for HIV-1 DNA genotypic resistance. <i>Journal of Clinical Virology</i> , 2020, 122, 104229.	1.6	14
29	Risk for Hepatitis E Virus Transmission by Solvent/Detergent-Treated Plasma. <i>Emerging Infectious Diseases</i> , 2020, 26, 2881-2886.	2.0	8
30	Tocilizumab for Hemophagocytic Syndrome in a Kidney Transplant Recipient With COVID-19. <i>Annals of Internal Medicine</i> , 2020, 173, 501-503.	2.0	21
31	Hepatitis E Virus: How It Escapes Host Innate Immunity. <i>Vaccines</i> , 2020, 8, 422.	2.1	13
32	No evidence of sexual transmission of HEV among individuals using HIV pre-exposure prophylaxis. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1495-1501.	1.0	7
33	Clinical performance of a rapid test compared to a microplate test to detect total anti SARS-CoV-2 antibodies directed to the spike protein. <i>Journal of Clinical Virology</i> , 2020, 130, 104528.	1.6	14
34	Evaluation of the Aptima,¢ transcription-mediated amplification assay (Hologic®) for detecting SARS-CoV-2 in clinical specimens. <i>Journal of Clinical Virology</i> , 2020, 129, 104541.	1.6	31
35	Hepatitis E, what's the real issue?. <i>Liver International</i> , 2020, 40, 43-47.	1.9	19
36	Insertions and Duplications in the Polyproline Region of the Hepatitis E Virus. <i>Frontiers in Microbiology</i> , 2020, 11, 1.	1.5	599

#	ARTICLE	IF	CITATIONS
37	Clinical Manifestations, Pathogenesis and Treatment of Hepatitis E Virus Infections. <i>Journal of Clinical Medicine</i> , 2020, 9, 331.	1.0	73
38	Optimized Hepatitis E Virus (HEV) Culture and Its Application to Measurements of HEV Infectivity. <i>Viruses</i> , 2020, 12, 139.	1.5	15
39	Classification of the Zoonotic Hepatitis E Virus Genotype 3 Into Distinct Subgenotypes. <i>Frontiers in Microbiology</i> , 2020, 11, 634430.	1.5	31
40	Plasma Hepatitis E Virus Kinetics in Solid Organ Transplant Patients Receiving Ribavirin. <i>Viruses</i> , 2019, 11, 630.	1.5	9
41	Hepatitis E and Allogeneic Hematopoietic Stem Cell Transplantation: A French Nationwide SFGM-TC Retrospective Study. <i>Viruses</i> , 2019, 11, 622.	1.5	9
42	Ribavirin for Chronic Hepatitis E Virus Infection in Ibrutinib-Exposed Patients. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz345.	0.4	6
43	Hepatitis E virus infections in Europe. <i>Journal of Clinical Virology</i> , 2019, 120, 20-26.	1.6	46
44	Failure to respond to ribavirin despite elevated intraerythrocyte zinc level in transplant patients with chronic hepatitis E virus infection. <i>Transplant Infectious Disease</i> , 2019, 21, e13050.	0.7	9
45	Performance characteristics of the VIDAS [®] ANTI-HEV IgM and IgG assays. <i>Journal of Clinical Virology</i> , 2019, 112, 10-14.	1.6	12
46	Hepatitis E Virus Infections among Patients with Acute Febrile Jaundice in Burkina Faso. <i>Viruses</i> , 2019, 11, 554.	1.5	7
47	Viral load and clinical manifestations of hepatitis E virus genotype 3 infections. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1139-1142.	1.0	12
48	Screening, diagnosis and risks associated with Hepatitis E virus infection. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 403-418.	2.0	23
49	Hepatitis E Virus (HEV) Open Reading Frame 2 Antigen Kinetics in Human-Liver Chimeric Mice and Its Impact on HEV Diagnosis. <i>Journal of Infectious Diseases</i> , 2019, 220, 811-819.	1.9	20
50	Seroprevalence of hepatitis E virus (HEV) in a general adult population in Northern Norway: the Troms ^Å study. <i>Medical Microbiology and Immunology</i> , 2019, 208, 715-725.	2.6	12
51	Should 12- or 24-week post-ribavirin follow-up be considered to define sustained virological response in transplant patients treated for chronic hepatitis E virus infection?. <i>Transplant Infectious Disease</i> , 2019, 21, e13065.	0.7	4
52	No evidence of occult hepatitis C or E virus infections in liver transplant patients with sustained virological response after therapy with direct acting agents. <i>Transplant Infectious Disease</i> , 2019, 21, e13093.	0.7	4
53	Vectorial Release of Hepatitis E Virus in Polarized Human Hepatocytes. <i>Journal of Virology</i> , 2019, 93, .	1.5	41
54	Hepatitis E virus genotype 3 and capsid protein in the blood and urine of immunocompromised patients. <i>Journal of Infection</i> , 2019, 78, 232-240.	1.7	31

#	ARTICLE	IF	CITATIONS
55	Monitoring hepatitis E virus fecal shedding to optimize ribavirin treatment duration in chronically infected transplant patients. <i>Journal of Hepatology</i> , 2019, 70, 206-209.	1.8	26
56	Baseline and Post-Treatment Hepatitis C NS5A Resistance in Relapsed Patients from a Multicentric Real-Life Cohort. <i>Antiviral Therapy</i> , 2018, 23, 307-314.	0.6	4
57	Chronic Hepatitis E in a Heart Transplant Patient: Sofosbuvir and Ribavirin Regimen Not Fully Effective. <i>Antiviral Therapy</i> , 2018, 23, 463-465.	0.6	27
58	Hepatitis E Virus Lifecycle and Identification of 3 Forms of the ORF2 Capsid Protein. <i>Gastroenterology</i> , 2018, 154, 211-223.e8.	0.6	145
59	Retreatment with direct-acting antivirals of genotypes 1-3-4 hepatitis C patients who failed an anti-NS5A regimen in real world. <i>Journal of Hepatology</i> , 2018, 68, 595-597.	1.8	9
60	Monitoring human enteric viruses in wastewater and relevance to infections encountered in the clinical setting: a one-year experiment in central France, 2014 to 2015. <i>Eurosurveillance</i> , 2018, 23, .	3.9	116
61	Hepatitis E prevalence in French Polynesian blood donors. <i>PLoS ONE</i> , 2018, 13, e0208934.	1.1	8
62	Performance of a commercial assay for detecting and quantifying HEV RNA in faeces. <i>Journal of Clinical Virology</i> , 2018, 109, 1-5.	1.6	6
63	Chronic Genotype 3 Hepatitis E in Pregnant Woman Receiving Infliximab and Azathioprine. <i>Emerging Infectious Diseases</i> , 2018, 24, 941-943.	2.0	18
64	Hepatitis E virus-associated cryoglobulinemia in solid organ transplant recipients. <i>Liver International</i> , 2018, 38, 2178-2189.	1.9	29
65	Diversity of hepatitis E virus genotype 3. <i>Reviews in Medical Virology</i> , 2018, 28, e1987.	3.9	33
66	A fully automated system using transcription-mediated amplification for the molecular diagnosis of hepatitis E virus in human blood and faeces. <i>Journal of Clinical Virology</i> , 2018, 105, 109-111.	1.6	7
67	Acute hepatitis E in French patients and neurological manifestations. <i>Journal of Infection</i> , 2018, 77, 220-226.	1.7	51
68	Transmission of hepatitis E virus infection to human-liver chimeric FRG mice using patient plasma. <i>Antiviral Research</i> , 2017, 141, 150-154.	1.9	46
69	Evaluation of two VIDAS [®] prototypes for detecting anti-HEV IgG. <i>Journal of Clinical Virology</i> , 2017, 89, 46-50.	1.6	7
70	Study of hepatitis E virus infection of genotype 1 and 3 in mice with humanised liver. <i>Gut</i> , 2017, 66, 920-929.	6.1	113
71	Characterization of the lipid envelope of exosome encapsulated HEV particles protected from the immune response. <i>Biochimie</i> , 2017, 141, 70-79.	1.3	98
72	Parsonage-Turner syndrome due to autochthonous acute genotype 3f hepatitis E virus infection in a nonimmunocompromised 55-year-old patient. <i>Journal of NeuroVirology</i> , 2017, 23, 615-620.	1.0	7

#	ARTICLE	IF	CITATIONS
73	Malignancies in hepatitis C virus-positive and -negative kidney transplant recipients: A case-controlled study. <i>Transplant Infectious Disease</i> , 2017, 19, e12725.	0.7	3
74	HEV infection in French HIV-infected patients. <i>Journal of Infection</i> , 2017, 74, 310-313.	1.7	27
75	Chronic hepatitis E virus infection in a cirrhotic patient. <i>Medicine (United States)</i> , 2017, 96, e7915.	0.4	14
76	Transfusion-acquired hepatitis E infection misdiagnosed as severe critical illness polyneuromyopathy in a heart transplant patient. <i>Transplant Infectious Disease</i> , 2017, 19, e12784.	0.7	14
77	Hepatitis E virus infection and acute non-traumatic neurological injury: A prospective multicentre study. <i>Journal of Hepatology</i> , 2017, 67, 925-932.	1.8	80
78	HEV and transfusion-recipient risk. <i>Transfusion Clinique Et Biologique</i> , 2017, 24, 176-181.	0.2	30
79	Sofosbuvir and Daclatasvir Anti-Viral Therapy Fails to Clear HEV Viremia and Restore Reactive T Cells in a HEV/HCV Co-Infected Liver Transplant Recipient. <i>Gastroenterology</i> , 2017, 152, 300-301.	0.6	51
80	Hepatitis E Virus Infection in Solid Organ Transplant Recipients, France. <i>Emerging Infectious Diseases</i> , 2017, 23, 353-356.	2.0	25
81	Rabbit Hepatitis E Virus Infections in Humans, France. <i>Emerging Infectious Diseases</i> , 2017, 23, 1191-1193.	2.0	139
82	Natural non-homologous recombination led to the emergence of a duplicated V3-NS5A region in HCV-1b strains associated with hepatocellular carcinoma. <i>PLoS ONE</i> , 2017, 12, e0174651.	1.1	1
83	Treatment of HEV Infection in Patients with a Solid-Organ Transplant and Chronic Hepatitis. <i>Viruses</i> , 2016, 8, 222.	1.5	36
84	Hepatitis E Pathogenesis. <i>Viruses</i> , 2016, 8, 212.	1.5	77
85	Quantification of HEV RNA by Droplet Digital PCR. <i>Viruses</i> , 2016, 8, 233.	1.5	26
86	New insights into the natural history of hepatitis E virus infection through a longitudinal study of multitransfused immunocompetent patients in France. <i>Journal of Viral Hepatitis</i> , 2016, 23, 569-575.	1.0	20
87	Extrahepatic manifestations of hepatitis E virus. <i>Liver International</i> , 2016, 36, 467-472.	1.9	98
88	Treatment of autochthonous acute hepatitis E with short-term ribavirin: a multicenter retrospective study. <i>Liver International</i> , 2016, 36, 328-333.	1.9	61
89	Analytical performance of the VERIS MDx system HCV assay for detecting and quantifying HCV RNA. <i>Journal of Clinical Virology</i> , 2016, 84, 7-11.	1.6	8
90	Hepatitis E, the neglected one. <i>Liver International</i> , 2016, 36, 130-134.	1.9	32

#	ARTICLE	IF	CITATIONS
91	Transmission of HCV NS5A Inhibitor-Resistant Variants Among HIV-Infected Men Who Have Sex With Men. <i>Clinical Infectious Diseases</i> , 2016, 63, ciw554.	2.9	17
92	Performance of an antigen assay for diagnosing acute hepatitis E virus genotype 3 infection. <i>Journal of Clinical Virology</i> , 2016, 79, 1-5.	1.6	44
93	Hepatitis E in Transplantation. <i>Current Infectious Disease Reports</i> , 2016, 18, 8.	1.3	14
94	Conventional and innate lymphocytes response at the acute phase of HEV infection in transplanted patients. <i>Journal of Infection</i> , 2016, 72, 723-730.	1.7	25
95	Mutation in the Hepatitis E Virus Polymerase and Outcome of Ribavirin Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1608-1614.	1.4	62
96	Hepatitis E Virus-Induced Cryoglobulinemic Glomerulonephritis in a Nonimmunocompromised Person. <i>American Journal of Kidney Diseases</i> , 2016, 67, 660-663.	2.1	58
97	High Proportion of Asymptomatic Infections in an Outbreak of Hepatitis E Associated With a Spit-Roasted Piglet, France, 2013. <i>Clinical Infectious Diseases</i> , 2016, 62, 351-357.	2.9	92
98	Outcome of Hepatitis E Virus Infection in Patients With Inflammatory Arthritides Treated With Immunosuppressants. <i>Medicine (United States)</i> , 2015, 94, e675.	0.4	50
99	An Early Viral Response Predicts the Virological Response to Ribavirin in Hepatitis E Virus Organ Transplant Patients. <i>Transplantation</i> , 2015, 99, 2124-2131.	0.5	60
100	Neurologic Disorders in Immunocompetent Patients with Autochthonous Acute Hepatitis E. <i>Emerging Infectious Diseases</i> , 2015, 21, 1928-34.	2.0	57
101	Ribavirin for Chronic Hepatitis Prevention among Patients with Hematologic Malignancies. <i>Emerging Infectious Diseases</i> , 2015, 21, 1466-1469.	2.0	41
102	Identification of a duplicated V3 domain in NS5A associated with cirrhosis and hepatocellular carcinoma in HCV-1b patients. <i>Journal of Clinical Virology</i> , 2015, 69, 203-209.	1.6	6
103	Temporal evolution of the distribution of hepatitis E virus genotypes in Southwestern France. <i>Infection, Genetics and Evolution</i> , 2015, 35, 50-55.	1.0	33
104	Naturally Occurring Resistance-Associated Variants of Hepatitis C Virus Protease Inhibitors in Poor Responders to Pegylated Interferon-Ribavirin. <i>Journal of Clinical Microbiology</i> , 2015, 53, 2195-2202.	1.8	21
105	Performance of a new rapid test for detecting anti-hepatitis E virus immunoglobulin M in immunocompetent and immunocompromised patients. <i>Journal of Clinical Virology</i> , 2015, 70, 101-104.	1.6	19
106	Protracted Fecal Shedding of HEV During Ribavirin Therapy Predicts Treatment Relapse. <i>Clinical Infectious Diseases</i> , 2015, 60, 96-99.	2.9	62
107	Hepatitis E virus: Chronic infection, extra-hepatic manifestations, and treatment. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, 20-27.	0.7	78
108	Influence of Polyproline Region and Macro Domain Genetic Heterogeneity on HEV Persistence in Immunocompromised Patients. <i>Journal of Infectious Diseases</i> , 2014, 209, 300-303.	1.9	53

#	ARTICLE	IF	CITATIONS
109	Hepatitis E Virus Infections in Blood Donors, France. <i>Emerging Infectious Diseases</i> , 2014, 20, 1914-1917.	2.0	118
110	Ribavirin for Chronic Hepatitis E Virus Infection in Transplant Recipients. <i>New England Journal of Medicine</i> , 2014, 370, 1111-1120.	13.9	436
111	Hepatitis E Virus Infection. <i>Clinical Microbiology Reviews</i> , 2014, 27, 116-138.	5.7	512
112	Characterization of the Polyproline Region of the Hepatitis E Virus in Immunocompromised Patients. <i>Journal of Virology</i> , 2014, 88, 12017-12025.	1.5	58
113	Hepatitis E Virus Reinfections in Solid-Organ-Transplant Recipients Can Evolve Into Chronic Infections. <i>Journal of Infectious Diseases</i> , 2014, 209, 1900-1906.	1.9	136
114	Telaprevir- and boceprevir-based tritherapies in real practice for F3-F4 pretreated hepatitis C virus patients. <i>World Journal of Hepatology</i> , 2014, 6, 660.	0.8	13
115	How Should Hepatitis E Virus Infection Be Defined in Organ-Transplant Recipients?. <i>American Journal of Transplantation</i> , 2013, 13, 1935-1936.	2.6	112
116	Performance of anti-HEV assays for diagnosing acute hepatitis E in immunocompromised patients. <i>Journal of Clinical Virology</i> , 2013, 58, 624-628.	1.6	98
117	Risk of zoonotic transmission of HEV from rabbits. <i>Journal of Clinical Virology</i> , 2013, 58, 357-362.	1.6	52
118	Hepatitis E virus. <i>MÃ©decine Et Maladies Infectieuses</i> , 2013, 43, 263-270.	5.1	20
119	Multicenter Quality Control of Hepatitis C Virus Protease Inhibitor Resistance Genotyping. <i>Journal of Clinical Microbiology</i> , 2013, 51, 1428-1433.	1.8	3
120	Performance of Two Commercial Assays for Detecting Hepatitis E Virus RNA in Acute or Chronic Infections. <i>Journal of Clinical Microbiology</i> , 2013, 51, 1913-1916.	1.8	48
121	Frequent Transient Hepatitis C viremia without Seroconversion among Healthcare Workers in Cairo, Egypt. <i>PLoS ONE</i> , 2013, 8, e57835.	1.1	20
122	An Analysis of the Benefit of Using HEV Genotype 3 Antigens in Detecting Anti-HEV IgG in a European Population. <i>PLoS ONE</i> , 2013, 8, e62980.	1.1	51
123	Hepatitis E Virus Quasispecies and the Outcome of Acute Hepatitis E in Solid-Organ Transplant Patients. <i>Journal of Virology</i> , 2012, 86, 10006-10014.	1.5	97
124	Genotype 3 Diversity and Quantification of Hepatitis E Virus RNA. <i>Journal of Clinical Microbiology</i> , 2012, 50, 897-902.	1.8	110
125	Hepatitis E Virus and the Kidney in Solid-Organ Transplant Patients. <i>Transplantation</i> , 2012, 93, 617-623.	0.5	170
126	Hepatitis E. <i>Lancet</i> , The, 2012, 379, 2477-2488.	6.3	805

#	ARTICLE	IF	CITATIONS
127	Epidemiological and virological characteristics of symptomatic acute hepatitis E in Greater Cairo, Egypt. <i>Clinical Microbiology and Infection</i> , 2012, 18, 982-988.	2.8	26
128	Low risk of hepatitis E virus reactivation after haematopoietic stem cell transplantation. <i>Journal of Clinical Virology</i> , 2012, 54, 152-155.	1.6	56
129	HIV-1 Tropism and Liver Fibrosis in HIV/HCV Co-Infected Patients. <i>PLoS ONE</i> , 2012, 7, e50289.	1.1	4
130	Hepatitis E Virus Strains in Rabbits and Evidence of a Closely Related Strain in Humans, France. <i>Emerging Infectious Diseases</i> , 2012, 18, 1274-81.	2.0	221
131	Hepatitis E virus-specific T-cell response after transplantation. <i>Hepatology</i> , 2012, 55, 1643-1643.	3.6	8
132	Hepatitis E Virus: What Transplant Physicians Should Know. <i>American Journal of Transplantation</i> , 2012, 12, 2281-2287.	2.6	53
133	NS3 Protease Polymorphism and Natural Resistance to Protease Inhibitors in French Patients Infected with HCV Genotypes 1-5. <i>Antiviral Therapy</i> , 2011, 16, 1093-1102.	0.6	50
134	Evolutionary history of hepatitis C virus genotype 5a in France, a multicenter ANRS study. <i>Infection, Genetics and Evolution</i> , 2011, 11, 496-503.	1.0	14
135	Hepatitis E Virus Infection without Reactivation in Solid-Organ Transplant Recipients, France. <i>Emerging Infectious Diseases</i> , 2011, 17, 30-37.	2.0	134
136	Hepatitis E Virus Antibodies in Blood Donors, France. <i>Emerging Infectious Diseases</i> , 2011, 17, 2309-2312.	2.0	314
137	Hepatitis E Virus Seroprevalence and Chronic Infections in Patients with HIV, Switzerland. <i>Emerging Infectious Diseases</i> , 2011, 17, 1074-1078.	2.0	123
138	Hepatitis E Virus Seroprevalence and Chronic Infections in Patients with HIV, Switzerland. <i>Emerging Infectious Diseases</i> , 2011, 17, 1074-1078.	2.0	64
139	Influence of Immunosuppressive Therapy on the Natural History of Genotype 3 Hepatitis-E Virus Infection After Organ Transplantation. <i>Transplantation</i> , 2010, 89, 353-360.	0.5	201
140	Characteristics of Autochthonous Hepatitis E Virus Infection in Solid-Organ Transplant Recipients in France. <i>Journal of Infectious Diseases</i> , 2010, 202, 835-844.	1.9	174
141	Pegylated Interferon- α for Treating Chronic Hepatitis E Virus Infection after Liver Transplantation. <i>Clinical Infectious Diseases</i> , 2010, 50, e30-e33.	2.9	180
142	Three-month pegylated interferon-alpha-2a therapy for chronic hepatitis E virus infection in a haemodialysis patient. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 2792-2795.	0.4	92
143	Ribavirin Therapy Inhibits Viral Replication on Patients With Chronic Hepatitis E Virus Infection. <i>Gastroenterology</i> , 2010, 139, 1612-1618.	0.6	265
144	New NS5B polymerase inhibitors for hepatitis C. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 963-975.	1.9	77

#	ARTICLE	IF	CITATIONS
145	Good Performance of Immunoglobulin M Assays in Diagnosing Genotype 3 Hepatitis E Virus Infections. <i>Vaccine Journal</i> , 2009, 16, 772-774.	3.2	80
146	Hepatitis E Virus Genotype 3 Diversity, France. <i>Emerging Infectious Diseases</i> , 2009, 15, 110-114.	2.0	141
147	Molecular Evidence of Patient-to-Patient Transmission of Hepatitis E Virus in a Hematology Ward. <i>Clinical Infectious Diseases</i> , 2009, 48, 373-374.	2.9	51
148	Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy. <i>Journal of Medical Virology</i> , 2009, 81, 2029-2035.	2.5	56
149	Comparison of liver stiffness, fibrotest and liver biopsy for assessment of liver fibrosis in kidney-transplant patients with chronic viral hepatitis. <i>Transplant International</i> , 2009, 22, 568-573.	0.8	28
150	Acute hepatitis E in south-west France over a 5-year period. <i>Journal of Clinical Virology</i> , 2009, 44, 74-77.	1.6	114
151	Laboratory evaluation of the UniCel DxI 800 analyser (Beckman Coulter) for detecting HBV and HCV serological markers. <i>Journal of Clinical Virology</i> , 2009, 44, 134-137.	1.6	9
152	High prevalence of anti-hepatitis E virus antibodies in blood donors from South West France. <i>Journal of Medical Virology</i> , 2008, 80, 289-293.	2.5	162
153	Serum concentrations of ribavirin and pegylated interferon and viral responses in patients infected with HIV and HCV. <i>Journal of Medical Virology</i> , 2008, 80, 1523-1529.	2.5	36
154	Hepatitis E Virus-Related Cirrhosis in Kidney and Kidney-Pancreas-Transplant Recipients. <i>American Journal of Transplantation</i> , 2008, 8, 1744-1748.	2.6	209
155	Hepatitis E Virus and Chronic Hepatitis in Organ-Transplant Recipients. <i>New England Journal of Medicine</i> , 2008, 358, 811-817.	13.9	1,197
156	Molecular Epidemiology and Interferon Susceptibility of the Natural Recombinant Hepatitis C Virus Strain RF1_2k/1b. <i>Journal of Infectious Diseases</i> , 2008, 198, 1448-1456.	1.9	47
157	Full-length genome sequences of hepatitis C virus subtype 4f. <i>Journal of General Virology</i> , 2007, 88, 2985-2990.	1.3	15
158	New Natural Intergenotypic (2/5) Recombinant of Hepatitis C Virus. <i>Journal of Virology</i> , 2007, 81, 4357-4362.	1.5	103
159	Genetic diversity of HCV genotype 2 strains in South Western France. <i>Journal of Medical Virology</i> , 2007, 79, 26-34.	2.5	24
160	Detection and quantitation of HCV RNA using real-time PCR after automated sample processing. <i>Journal of Medical Virology</i> , 2007, 79, 1821-1826.	2.5	15
161	Twenty-four hour kinetics of hepatitis C virus and antiviral effect of alpha-interferon. <i>Journal of Medical Virology</i> , 2006, 78, 365-371.	2.5	14
162	Acute hepatitis and renal function impairment related to infection by hepatitis E virus in a renal allograft recipient. <i>American Journal of Kidney Diseases</i> , 2005, 45, 193-196.	2.1	55

#	ARTICLE	IF	CITATIONS
163	Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection. Journal of Medical Virology, 2005, 77, 66-69.	2.5	50
164	Heterogeneity of hepatitis C virus genotype 4 strains circulating in south-western France. Journal of General Virology, 2005, 86, 107-114.	1.3	71
165	Convenient Biological Assay for Polyethylene Glycol-Interferons in Patients with Hepatitis C. Antimicrobial Agents and Chemotherapy, 2004, 48, 3610-3612.	1.4	6
166	Hepatitis C Virus Genotype 5: Epidemiological Characteristics and Sensitivity to Combination Therapy with Interferon α plus Ribavirin. Journal of Infectious Diseases, 2004, 189, 1397-1400.	1.9	53
167	Hepatitis E in the south west of France in individuals who have never visited an endemic area. Journal of Medical Virology, 2004, 74, 419-424.	2.5	232